Patient and graft demographics of 113 DCBT recipients and 226 units
Characteristics . | Value . |
---|---|
Median age (range), y | 41 (1-69) |
Male, N (%) | 61 (54) |
Recipient CMV seropositive, N (%) | 61 (54) |
Diagnosis, N (%) | |
Acute leukemia | 58 (51) |
MDS/CML/other MPD | 8 (7) |
NHL/HL/CLL | 47 (42) |
Conditioning, N (%) | |
High-dose myeloablative | |
Cy 120/Flu 75/TBI 1320-1375 cGy | 32 (28) |
Clo 100/Mel 140/Thio 10 | 5 (4) |
Reduced intensity | |
Cy 50/Flu 150/Thio 10/TBI 400 cGy | 39 (35) |
Mel 140/Flu 150 | 8 (7) |
Nonmyeloablative | |
Cy 50/Flu 150/TBI 200 cGy | 28 (25) |
6-TG, Flu 150/TBI 400 cGy | 1 (1) |
Donor-recipient HLA-A, -B antigen, -DRB1 allele match, N (%) | |
6/6 | 9 (4) |
5/6 | 115 (51) |
4/6 | 102 (45) |
Median infused TNC dose (range) | |
Larger unit | 2.76 × 107/kg (1.46-7.19) |
Smaller unit | 2.02 × 107/kg (1.13-4.51) |
Median infused CD34+dose (range) | |
Larger unit | 1.33 × 105/kg (0.41-4.51) |
Smaller unit | 0.68 × 105/kg (0.13-2.0) |
Characteristics . | Value . |
---|---|
Median age (range), y | 41 (1-69) |
Male, N (%) | 61 (54) |
Recipient CMV seropositive, N (%) | 61 (54) |
Diagnosis, N (%) | |
Acute leukemia | 58 (51) |
MDS/CML/other MPD | 8 (7) |
NHL/HL/CLL | 47 (42) |
Conditioning, N (%) | |
High-dose myeloablative | |
Cy 120/Flu 75/TBI 1320-1375 cGy | 32 (28) |
Clo 100/Mel 140/Thio 10 | 5 (4) |
Reduced intensity | |
Cy 50/Flu 150/Thio 10/TBI 400 cGy | 39 (35) |
Mel 140/Flu 150 | 8 (7) |
Nonmyeloablative | |
Cy 50/Flu 150/TBI 200 cGy | 28 (25) |
6-TG, Flu 150/TBI 400 cGy | 1 (1) |
Donor-recipient HLA-A, -B antigen, -DRB1 allele match, N (%) | |
6/6 | 9 (4) |
5/6 | 115 (51) |
4/6 | 102 (45) |
Median infused TNC dose (range) | |
Larger unit | 2.76 × 107/kg (1.46-7.19) |
Smaller unit | 2.02 × 107/kg (1.13-4.51) |
Median infused CD34+dose (range) | |
Larger unit | 1.33 × 105/kg (0.41-4.51) |
Smaller unit | 0.68 × 105/kg (0.13-2.0) |
6-TG, 6-thioguanine; CLL, chronic lymphocytic leukemia; Clo, clofarabine; CML, chronic myelogenous leukemia; CMV, cytomegalovirus; Cy, cyclophosphamide; Flu, fludarabine; HL, Hodgkin lymphoma; MDS, myelodysplastic syndrome; Mel, melphalan; MPD, myeloproliferative disease; NHL, non-Hodgkin lymphoma; TBI, total body irradiation; Thio, Thiotepa; TNC, total nucleated cell dose.